ALADDIN Education

The ALADDIN Podcast

Education EN ↓ 11 episodes

A whole new world of paediatric cancer drug development...The ALADDIN project is a multi-stakeholder educational programme on regulatory science in drug development for children's cancers. Whilst progress has been made to treat children's cancers, there is still a way to go and hope lies in developing new medicines that are more effective and cause less long-term harm. In our brand new podcast, we'll be welcoming a range of guests from the world of paediatric oncology to demystify some of the complex issues that face this specialised field.

Be sure to visit the podcast's website and support the creator: aladdin-education.eu

Author

ALADDIN Education

Category

Education

Podcast website

aladdin-education.eu

Latest episode

Mar 20, 2025

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android almost 10M downloads · 4.7+ rating iOS soon

Episodes

Dr Ameeta Retzer & Dr Victoria Forster 20.03.2025

In the 10th episode of the ALADDIN podcast, our host Sara welcomes Dr Ameeta Retzer & Dr Victoria Forster to discuss patient reported outcomes (PROs) and the role of patient engagement in paediatric oncology research.

The role of patient advocates in research 03.02.2025

In this episode of the ALADDIN podcast, expert advocates Nick Bird, Nicole Scobie and Antonia Palmer share their experiences of engaging in drug development research.

Demystifying academic clinical trials in paediatric oncology 03.12.2024

In this episode of the ALADDIN podcast, host Sara sits down with Professor of paediatric oncology Pam Kearns, and expert patient advocate Donna Ludwinski to discuss the role of academic clinical trials in developing new medicines for children with cancer.

Prof Michel Zwaan 23.10.2024

Prof Michel Zwaan is a paediatric oncologist working in the Prinses Maxima Centrum in the Netherlands. In this episode, he discusses the involvement of the pharmaceutical industry in researching new drugs for children with cancer.

Professor Gilles Vassal 16.09.2024

What is Health Technology Assessment and why is it important for developing new medicines? In this episode of the ALADDIN podcast, Prof. Gilles Vassal gives some insight in preparation for the next public ALADDIN webinar on HTAs. Secure your place at the webinar today: https://portal.aladdin-education.eu/webinar/108

Delphine Heenen & Dr. Davy Chiodin 09.08.2024

In this episode, Sara chats with Delphine Heenen & Dr. Davy Chiodin about how innovative approaches like repurposing drugs and rescuing shelved drugs can bring solutions in the development of paediatric drugs.

Dr Steve DuBois & Dr Julia Glade-Bender 19.06.2024

In this episode of the ALADDIN podcast, we talk to paediatric oncologists Dr Steve DuBois and Dr Julia Glade-Bender about the challenges of delivering clinical trials for children with cancer.

Meet the ALADDIN students 23.05.2024

In this episode, our host Sara chats to some of the students involved in the various ALADDIN activities about their learnings and experience in the programme so far.

Begonya Nafira 10.04.2024

In this month's episode, our host Sara speaks to patient engagement and involvement expert Begonya Nafira. Begonya is based at the Sant Joan de Déu Hospital in Barcelona, and coordinates their patient engagement programme for children's clinical trials.

Dr Teresa De Rojas 12.03.2024

In our very first episode, ALADDIN Coordinator Dr Teresa De Rojas gives an overview of the programme and how it has developed so far.

Welcome to the ALADDIN Podcast 16.02.2024

The brand new ALADDIN podcast is here! Meet our host, Sara Wakeling, and learn more about the new podcast about drug development for children with cancer.

Listen to the The ALADDIN Podcast podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.